Advances in immune checkpoint inhibitors therapy for small cell lung cancer

Abstract Background As one of the most aggressive neuroendocrine tumors, small cell lung cancer (SCLC) has the most disappointing prognosis of all lung cancers. Although SCLC responds well to initial chemotherapy, the majority of patients experience disease recurrence within one year, and patient su...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Longhui Li, Yangyueying Liang, Minghui Yu, Lu Zhao, Qingyun Mei, Yongchao Yu, Na Wang, Dou Zhang, Ziwei Wang, Yingjie Jia, Fanming Kong
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-05-01
coleção:	Cancer Medicine
Assuntos:	clinical trials immune checkpoint inhibitors SCLC tumor microenvironment
Acesso em linha:	https://doi.org/10.1002/cam4.5659
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!